… of non-β-lactam inhibitors. Two other combinations have not yet reached late-stage clinical
trials … Unfortunately, most clinical isolates bearing class B enzymes also encode either class A …

… catarrhalis clinical isolates are sensitive to amoxicillin/clavulanate, which is comparable
or superior to most oral cephalosporins.[8] In the same study, less than 3% of S. pneumoniae …

… The combination of vaborbactam and meropenem 5 was tested against more than 300
Enterobacteriaceae clinical isolates, the majority of which carried KPC genes. A fixed …

… Clinical data on optimal dosing (intermittent versus … As hydrophilic drugs, β-lactams and
β-lactamase inhibitors have a … the disposition of both β-lactams and β-lactamase inhibitors (18). …

… In a study that evaluated >200 P aeruginosa clinical isolates, most of which were not
susceptible to imipenem, the addition of relebactam restored susceptibility of the majority of the …

Novel β-lactam–β-lactamase inhibitor combinations (BLBLIs) are in clinical development for
the treatment of infections caused by carbapenem-resistant and difficult-to-treat resistant (…

… β-lactamase inhibitor. Unlike the old β-lactamase inhibitors, boronic acid β-lactamase inhibitors
… serine side chain of the β-lactamase (8). They are also resistant to hydrolysis by serine …

… ” β-lactam-β-lactamase inhibitor combination that targets all clinically important β-lactamases
(eg… and the novel β-lactam-β-lactamase inhibitor combinations are discussed in this article. …

… assessed clinical outcomes in patients with CPE-infections treated with the novel BLBLIs as
mono- or combo-… Available evidence on combination therapy is scarce and mainly limited to …

… Unsurprisingly, resistance to ceftolozane in clinical isolates may occur through
hyperproduction of the pseudomonal AmpC cephalosporinase that confers resistance to other …